- Home
- EEA vs BYSI Comparison
EEA vs BYSI Comparison
Compare EEA & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- BYSI
- Stock Information
- Founded
- EEA 1986
- BYSI 2010
- Country
- EEA Germany
- BYSI United States
- Employees
- EEA N/A
- BYSI N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- BYSI Health Care
- Exchange
- EEA Nasdaq
- BYSI Nasdaq
- Market Cap
- EEA 67.9M
- BYSI 80.6M
- IPO Year
- EEA N/A
- BYSI 2017
- Fundamental
- Price
- EEA $10.66
- BYSI $1.90
- Analyst Decision
- EEA
- BYSI
- Analyst Count
- EEA 0
- BYSI 0
- Target Price
- EEA N/A
- BYSI N/A
- AVG Volume (30 Days)
- EEA 9.2K
- BYSI 26.9K
- Earning Date
- EEA 01-01-0001
- BYSI 08-13-2025
- Dividend Yield
- EEA 1.92%
- BYSI N/A
- EPS Growth
- EEA N/A
- BYSI N/A
- EPS
- EEA N/A
- BYSI N/A
- Revenue
- EEA N/A
- BYSI N/A
- Revenue This Year
- EEA N/A
- BYSI N/A
- Revenue Next Year
- EEA N/A
- BYSI N/A
- P/E Ratio
- EEA N/A
- BYSI N/A
- Revenue Growth
- EEA N/A
- BYSI N/A
- 52 Week Low
- EEA $7.45
- BYSI $0.98
- 52 Week High
- EEA $9.26
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- EEA 58.73
- BYSI 50.08
- Support Level
- EEA $10.42
- BYSI $1.67
- Resistance Level
- EEA $10.83
- BYSI $1.84
- Average True Range (ATR)
- EEA 0.19
- BYSI 0.13
- MACD
- EEA -0.01
- BYSI 0.02
- Stochastic Oscillator
- EEA 60.33
- BYSI 65.53
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.